Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Myelodysplastic Syndromes 10Leukemia, Myeloid, Acute 7Hematologic Neoplasms 7Leukemia 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Non-Hodgkin 4Lymphoma 4Primary Immunodeficiency Diseases 3Cytopenia 3Anemia, Aplastic 3Thalassemia 2Osteopetrosis 2Multiple Myeloma 2Hemoglobinopathies 2Fanconi Anemia 2Anemia, Sickle Cell 2Anemia, Diamond-Blackfan 2Anemia 2Uveal Melanoma 1Thymoma 1Thymic epithelial tumor 1Prostatic Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hodgkin Disease 1Hematologic Diseases 1Graft vs Host Disease 1Castrate Resistant Prostate Cancer (CRPC) 1Anemia, Refractory, with Excess of Blasts 1

Interventions

AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Castrate Resistant Prostate Cancer (CRPC) × AP 1903 reagent × Clear all
NCT00868595 2019-10-08

MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer

Bellicum Pharmaceuticals

Phase 1 Completed
18 enrolled
Genitourinary

Castrate Resistant Prostate Cancer (CRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡